GT Biopharma, Inc. (GTBP) Valuation — DCF, Graham & Comparables

GT Biopharma, Inc. (GTBP) — Price $7.81 HealthcareBiotechnology — NASDAQ

Latest reported results:

Valuation dashboard for GT Biopharma, Inc. (GTBP) with P/E N/A, P/B 3.40, EV/EBITDA -0.48 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.

Analysis Summary

Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.

At the current price of $7.81, GTBP has negative trailing earnings (P/E not meaningful) and an ROE of -443.08%. Market capitalisation stands at $10M.

Balance sheet quality for GTBP: current ratio of 3.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Valuation Ratios

Price / Book3.40
EV / EBITDA-0.48
Dividend Yield0.00%

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
GTBPGT Biopharma, Inc.$10M3.40-443.1%
0QZU.LVertex Pharmaceuticals Incorporated$131.8B
VRTXVertex Pharmaceuticals Incorporated$130.3B29.686.4523.3%
0R2M.LRegeneron Pharmaceuticals, Inc.$84.0B
REGNRegeneron Pharmaceuticals, Inc.$79.8B18.792.5713.8%
ARGXargenx SE$61.2B36.307.4021.7%
MRNAModerna, Inc.$57.8B1.34-39.2%
RVMDRevolution Medicines, Inc.$41.7B15.96-96.4%

Price

Price$7.81
Market Cap$10M
ExchangeNASDAQ
CountryUS

Profitability

Return on Equity-443.08%
Return on Invested Capital-457.75%
Return on Assets-381.53%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB

Explore sector: Healthcare · Biotechnology

More sections of GTBP: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks